Join the Oncology Voice Network. Join for Free
"The Road Less Traveled: Leveraging an Unconventional Career Path"
Medical Science Liaison Marc Bernarducci MSL career advice unconventional career path transitioning to industry

"The Road Less Traveled: Leveraging an Unconventional Career Path"


Share This Article


Summary

In this episode, Tom Caravela is joined by Marc Bernarducci to explore the evolving role of Medical Science Liaisons. Marc shares insights from his educational journey and transition into the industry, highlighting the significance of networking and tenacity. He emphasizes patience and coachability during job searches and new roles, and discusses the complexities of the MSL position, including learning from mistakes. The conversation shifts to adapting to digital platforms and preparing for the post-COVID landscape, stressing the importance of adaptability. Marc concludes with valuable advice for aspiring MSLs, followed by closing remarks and holiday wishes.

Marc Bernarducci, Sr Medical Science Liaison shares ideas on leveraging an unconventional career path to find success.

In this episode we discuss:

  • Marc’s education and where his career began
  • What made him want to transition to industry and how did he go about it
  • How he landed in medical affairs and why he wanted to be an MSL
  • His perspective on “unconventional” career path
  • His advice for others who are looking to break into their first MSL role
  • His other advice to those that are looking to build a career in Medical Affairs

Click for Source
Medical Science Liaison, Marc Bernarducci, MSL career advice, unconventional career path, transitioning to industry

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Explore OVN